Showing 1 - 6 results of 6 for search 'Markus Gräler', query time: 0.04s Refine Results
  1. 1
    Extraction and Quantification of Sphingosine 1-Phosphate (S1P)

    Extraction and Quantification of Sphingosine 1-Phosphate (S1P) by Christina-Maria Reimann, Markus Gräler

    Published 2016-05-01
    Get full text
    Article
  2. 2
    Systematic Metabolic Profiling Identifies De Novo Sphingolipid Synthesis as Hypha Associated and Essential for Candida albicans Filamentation

    Systematic Metabolic Profiling Identifies De Novo Sphingolipid Synthesis as Hypha Associated and Essential for Candida albicans Filamentation by Enrico Garbe, Franziska Gerwien, Dominik Driesch, Tina Müller, Bettina Böttcher, Markus Gräler, Slavena Vylkova

    Published 2022-12-01
    Get full text
    Article
  3. 3
    HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis

    HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis by Katherine Sattler, Isa Lehmann, Markus Gräler, Martina Bröcker-Preuss, Raimund Erbel, Gerd Heusch, Bodo Levkau

    Published 2014-06-01
    Get full text
    Article
  4. 4
    Lipid metabolic signatures deviate in sepsis survivors compared to non-survivors

    Lipid metabolic signatures deviate in sepsis survivors compared to non-survivors by Waqas Khaliq, Peter Großmann, Sophie Neugebauer, Anna Kleyman, Roberta Domizi, Sara Calcinaro, David Brealey, Markus Gräler, Michael Kiehntopf, Sascha Schäuble, Mervyn Singer, Gianni Panagiotou, Michael Bauer

    Published 2020-01-01
    Get full text
    Article
  5. 5
    A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1

    A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 by Anna-Maria Neßlauer, Anne Gläser, Markus Gräler, Robby Engelmann, Brigitte Müller-Hilke, Marcus Frank, Christine Burstein, Arndt Rolfs, John Neidhardt, Andreas Wree, Martin Witt, Anja U. Bräuer

    Published 2019-06-01
    Get full text
    Article
  6. 6
    Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial

    Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial by Peter Schlattmann, Thomas Lehmann, Tim Rahmel, Johannes Roth, Peter Kranke, Frank M Brunkhorst, Andreas Greinacher, Patrick Meybohm, Philipp Helmer, Stefan Hagel, Florian Rißner, Michael Bauer, Matthias Gründling, Sven-Olaf Kuhn, Christian Fuchs, Luis Ferreira Moita, Frank Bloos, Matthias Michael, Ulrike Schumacher, Matthias Unterberg, Daniel Thomas-Rüddel, Christiane Helbig, Johannes Ehler, Heiko Schenk, Thomas Köcher, Markus Gräler, Ann-Julika Heger, Sebastian Weis, Karen Dlubatz, Jakob Hammersen, Katja Leonhardt, René Markgraf, Franziska Röstel, Nicole Schwarze, Mariann Städtler, Wolfgang Vivas-Varela, Andre Hagedorn, Andrea Wittkowski, Florian Rumpf, Tobias Haas, Sebastian Hottenrott, Eva Kranke, Marianne Neuf, Anke Reppchen, Daniel Röder, Julius Schmidt

    Published 2024-04-01
    Get full text
    Article

Search Tools: